PMID- 37954563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231122
IS  - 2514-2119 (Electronic)
IS  - 2514-2119 (Linking)
VI  - 7
IP  - 11
DP  - 2023 Nov
TI  - Antiarrhythmic effects of baroreceptor activation therapy in chronic heart 
      failure: a case report.
PG  - ytad520
LID - 10.1093/ehjcr/ytad520 [doi]
LID - ytad520
AB  - BACKGROUND: Autonomic imbalance represents a keystone of chronic heart failure 
      (HF) with substantial clinical and prognostic implications. Baroreceptor 
      activation therapy (BAT) is a new therapeutic strategy to target the autonomic 
      dysbalance by electrical stimulation of carotid baroreceptors. Besides its known 
      beneficial effects on HF parameters, BAT is also supposed to trigger potential 
      antiarrhythmic effects, which may additionally contribute to HF improvement. CASE 
      SUMMARY: We report on a 70-year-old male with progredient shortness of breath and 
      advanced HF in the context of an extensive cardiovascular history. After 
      optimization of pharmacologic and device-related therapy, the decision was made 
      to implant a BAT system (Barostim Neo, CVRx) to improve functional cardiac 
      parameters and support symptomatic improvement. Implantation was associated with 
      an overall clinical improvement assessed during outpatient visits every 6 months. 
      Frequency of ventricular arrhythmic events declined, and atrial fibrillation 
      ceased spontaneously. Echocardiography revealed an amelioration in left 
      ventricular systolic function. Numbers of HF hospitalization decreased after 
      Barostim implantation. DISCUSSION: We present a patient with an extensive 
      cardiovascular history and fully exploited pharmacologic and device-related 
      therapy, who showed improvement in New York Heart Association (NYHA) functional 
      classification, left ventricular systolic function, and reduction of arrhythmic 
      events following implantation of the BAT device. This case presents an additional 
      positive potential of BAT for HF patients in terms of reduction of arrhythmia 
      burden. These results should be confirmed by further clinical trials.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Wang, Dong
AU  - Wang D
AUID- ORCID: 0009-0008-5515-1742
AD  - Department of Cardiology and Angiology, Hannover Medical School, 
      Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
FAU - Veltmann, Christian
AU  - Veltmann C
AD  - Department of Cardiology and Angiology, Hannover Medical School, 
      Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
FAU - Bauersachs, Johann
AU  - Bauersachs J
AUID- ORCID: 0000-0002-9341-117X
AD  - Department of Cardiology and Angiology, Hannover Medical School, 
      Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
FAU - Duncker, David
AU  - Duncker D
AUID- ORCID: 0000-0003-2996-6338
AD  - Department of Cardiology and Angiology, Hannover Medical School, 
      Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
LA  - eng
PT  - Case Reports
DEP - 20231020
PL  - England
TA  - Eur Heart J Case Rep
JT  - European heart journal. Case reports
JID - 101730741
PMC - PMC10633707
OTO - NOTNLM
OT  - Arrhythmias
OT  - Atrial fibrillation
OT  - BAT
OT  - Baroreceptor activation therapy
OT  - Case report
OT  - Heart failure
COIS- Conflict of interest: D.W. does not have any conflicts of interest to declare. 
      C.V. received modest honorary for lectures and consultant activities from Abbott, 
      Biotronik, and Medtronic. J.B. received honoraria for lectures/consulting from 
      Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, 
      BMS, Amgen, Corvia, Norgine, Edwards, and Roche, not related to this article, and 
      research support for the department from Zoll, CVRx, Abiomed, Norgine, and Roche, 
      not related to this article. D.D. received modest lecture honorary, travel 
      grants, and/or a fellowship grant from Abbott, AstraZeneca, Biotronik, Boehringer 
      Ingelheim, Boston Scientific, CVRx, Medtronic, Microport, Pfizer, and Zoll.
EDAT- 2023/11/13 06:43
MHDA- 2023/11/13 06:44
PMCR- 2023/10/20
CRDT- 2023/11/13 04:34
PHST- 2023/05/13 00:00 [received]
PHST- 2023/10/01 00:00 [revised]
PHST- 2023/10/16 00:00 [accepted]
PHST- 2023/11/13 06:44 [medline]
PHST- 2023/11/13 06:43 [pubmed]
PHST- 2023/11/13 04:34 [entrez]
PHST- 2023/10/20 00:00 [pmc-release]
AID - ytad520 [pii]
AID - 10.1093/ehjcr/ytad520 [doi]
PST - epublish
SO  - Eur Heart J Case Rep. 2023 Oct 20;7(11):ytad520. doi: 10.1093/ehjcr/ytad520. 
      eCollection 2023 Nov.